Artiva Biotherapeutics Inc
ARTV
NASDAQ
Biotechnology
$11.45
USD
+0.15 (+1.33%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $552.46M
Volume 264.4K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-90.82M
TTM
-20.9%
YoY
Operating Cash Flow
$-75.23M
TTM
-8.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.9 | 5.3 | 4.9 | 5.1 | 5.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 22.8 | 22.9 | 21.9 | 24.4 | 26.9 |
Operating Income | -22.8 | -22.9 | -21.9 | -24.4 | -26.9 |
EBITDA | -22.2 | -22.2 | -21.3 | -23.8 | -26.2 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | 0.0 | -0.0 |
Total Other Income / Expense | 1.6 | 1.4 | 1.2 | 0.9 | 1.9 |
Income Before Income Taxes | -21.3 | -21.5 | -20.8 | -23.5 | -25.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -21.3 | -21.5 | -20.8 | -23.5 | -25.0 |
Consolidated Net Income / Loss | -21.3 | -21.5 | -20.8 | -23.5 | -25.0 |
Net Income Attributable to Common Shareholders | -21.3 | -21.5 | -20.8 | -23.5 | -25.0 |
Basic EPS | -$0.87 | -$0.88 | -$0.85 | -$0.95 | -$0.63 |
Diluted EPS | -$0.87 | -$0.88 | -$0.85 | -$0.95 | -$0.63 |
Basic Shares Outstanding | 24.4M | 24.5M | 24.6M | 24.7M | 39.4M |
Diluted Shares Outstanding | 24.4M | 24.5M | 24.6M | 24.7M | 39.4M |